Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.

Radhika Bansal,Paschalis Vergidis,Pritish K. Tosh,John W. Wilson,Matthew A. Hathcock,N. Nora Bennani,Jonas Paludo,Jose C. Villasboas,Yucai Wang,Stephen M. Ansell,Patrick B. Johnston,Catherine M. Freeman,Yi Lin

Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.

2021

Radhika Bansal
Paschalis Vergidis
Pritish K. Tosh
John W. Wilson
Matthew A. Hathcock
N. Nora Bennani
Jonas Paludo
Jose C. Villasboas
Yucai Wang
Stephen M. Ansell
Patrick B. Johnston
Catherine M. Freeman
Yi Lin

7555Background: While CAR-T therapy is not myelo-ablative, patients with aggressive lymphoma treated with CD19 chimeric antigen receptor T cell therapy (CAR-T) are lymphodepleted and have prolonged...

Keywords:

Medicine
Aggressive lymphoma
Lymphoma
Cancer research
Titer
Chimeric Antigen Receptor T-Cell Therapy
CD19

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations